Health Insurance - Ovarian Cancer Prevention With Salpingectomy - Required Coverage
HB0633 requires certain Maryland health insurers, nonprofit health service plans, and health maintenance organizations to cover opportunistic salpingectomy when it is performed for ovarian cancer prevention. The bill specifically prohibits copayments, coinsurance, and deductibles for that coverage, except that a high-deductible health plan may still apply its deductible to the service as allowed under federal tax law. The mandate applies to policies, contracts, and health benefit plans issued, delivered, or renewed in Maryland on or after January 1, 2027.
The bill also directs the Maryland Health Care Commission to study by December 1, 2026, whether coverage should be expanded to nonopportunistic salpingectomy for individuals who are not at high risk of ovarian cancer. That study must consider professional guidance and compare the effectiveness of nonopportunistic versus opportunistic salpingectomy, and the Commission must report its findings to the Senate Finance Committee and House Health Committee.
HB0633 adds a new mandated health insurance benefit in the Insurance Article, requiring coverage for opportunistic salpingectomy as an ovarian cancer prevention measure and limiting cost-sharing for most plans. It affects insurers, nonprofit health service plans, and HMOs that issue or deliver health coverage in Maryland, while preserving an exception for high-deductible health plans. The bill also creates a legislative study requirement for the Maryland Health Care Commission, which may inform future changes to mandated benefits and preventive gynecologic care coverage.
The available context suggests generally favorable legislative sentiment, as the House committee reported the bill favorably with amendments and the House adopted it. No committee transcript or recorded vote details are provided, but the bill’s progression indicates support for expanding preventive women’s health coverage. The inclusion of a study requirement also suggests an effort to balance the coverage mandate with further review of broader clinical and cost implications.
The main policy issue is the scope of the coverage mandate: supporters appear to favor guaranteed access to opportunistic salpingectomy for ovarian cancer prevention without out-of-pocket costs, while the study provision reflects ongoing uncertainty about whether coverage should extend to nonopportunistic salpingectomy for lower-risk individuals. Another point of potential contention is the cost-sharing prohibition, though the bill preserves a high-deductible health plan exception to align with federal rules. No explicit opposition is shown in the provided materials, but the mandated-benefit aspect and future expansion question are the likely areas of debate.